{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:02:36Z","timestamp":1781881356347,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023544","name":"National Taiwan University Hospital Hsin-Chu Branch Hsin-Chu Hospital","doi-asserted-by":"publisher","award":["113-BIH026"],"award-info":[{"award-number":["113-BIH026"]}],"id":[{"id":"10.13039\/501100023544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119102","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:34:37Z","timestamp":1770694477000},"page":"119102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti\u2013PD1 in hepatocellular carcinoma"],"prefix":"10.1016","volume":"196","author":[{"given":"Yu-Chen","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Chuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-3761","authenticated-orcid":false,"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Te","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Chi","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Shu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chuan","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Tzu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib1","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA a cancer journal clinicians"},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"10088","key":"10.1016\/j.biopha.2026.119102_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2026.119102_bib4","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119102_bib6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119102_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2026.119102_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.755433","article-title":"Immunogenic cell death and immunomodulatory effects of cabozantinib","volume":"11","author":"Scirocchi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119102_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2024.09.047","article-title":"Cabozantinib-encapsulated and maytansine-conjugated high-density lipoprotein for immunotherapy in colorectal cancer","volume":"376","author":"Zheng","year":"2024","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119102_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106646","article-title":"In situ vaccination followed by intramuscular poly-ICLC injections for the treatment of hepatocellular carcinoma in mouse models","volume":"188","author":"Weng","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119102_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"issue":"14","key":"10.1016\/j.biopha.2026.119102_bib13","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1073\/pnas.1602023113","article-title":"PGE2 induced in and released by dying cells functions as an inhibitory DAMP","volume":"113","author":"Hangai","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib14","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1038\/s41467-020-19970-9","article-title":"Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death","volume":"11","author":"Hayashi","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib15","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41467-022-29026-9","article-title":"Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors","volume":"13","author":"Nikolos","year":"2022","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2026.119102_bib16","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/TP.0000000000004425","article-title":"Therapeutic effects of Anti-PD1 immunotherapy on hepatocellular carcinoma under administration of tacrolimus","volume":"107","author":"Hsu","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.biopha.2026.119102_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.572861","article-title":"Metronomic celecoxib therapy in clinically available dosage ablates hepatocellular carcinoma via suppressing cell invasion, growth, and stemness in pre-clinical models","volume":"10","author":"Yeh","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib18","article-title":"Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model","volume":"2","author":"Yamaguchi","year":"2020","journal-title":"NeuroOncol. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib19","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1038\/s41467-025-62934-0","article-title":"The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active","volume":"16","author":"Sequera","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119102_bib20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s12072-023-10603-z","article-title":"Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma","volume":"18","author":"Suzuki","year":"2024","journal-title":"Hepatol. Int."},{"issue":"10","key":"10.1016\/j.biopha.2026.119102_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009690","article-title":"Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma","volume":"12","author":"DeAzevedo","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119102_bib22","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","article-title":"Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma","volume":"28","author":"Esteban-Fabr\u00f3","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119102_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010472","article-title":"Ethanol inhibits the growth and metastasis of hepatocellular carcinoma by inducing immunogenic cell death","volume":"13","author":"Hsu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119102_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.biopha.2026.119102_bib25","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","article-title":"Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence","volume":"18","author":"Bergerot","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.biopha.2026.119102_bib26","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.22.00972","article-title":"Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial","volume":"41","author":"Yau","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119102_bib27","article-title":"Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results","volume":"4","author":"Saeed","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.biopha.2026.119102_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101917","article-title":"Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression Cabozantinib ICIs in pretreated HCC patients","volume":"30","author":"Lai","year":"2025","journal-title":"Ann. HEPATOLOGY"},{"issue":"8011","key":"10.1016\/j.biopha.2026.119102_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","article-title":"PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function","volume":"629","author":"Morotti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119102_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fimmu.2016.00222","article-title":"Molecular mechanisms for cAMP-mediated immunoregulation in T cells\u2013role of anchored protein kinase a signaling units","volume":"7","author":"Wehbi","year":"2016","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119102_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/imm.13417","article-title":"Prostaglandin E2 directly inhibits the conversion of inducible regulatory T cells through EP2 and EP4 receptors via antagonizing TGF-\u03b2 signalling","volume":"164","author":"Goepp","year":"2021","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.biopha.2026.119102_bib32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.biopha.2026.119102_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119102_bib34","first-page":"4360","article-title":"Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization","volume":"13","author":"Xun","year":"2021","journal-title":"Am. J. Transl. Res."},{"issue":"24","key":"10.1016\/j.biopha.2026.119102_bib35","doi-asserted-by":"crossref","first-page":"15864","DOI":"10.1021\/acsnano.4c02947","article-title":"Celecoxib augments paclitaxel-induced immunogenic cell death in triple-negative breast cancer","volume":"18","author":"Qian","year":"2024","journal-title":"ACS nano"},{"issue":"7","key":"10.1016\/j.biopha.2026.119102_bib36","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1541-7786.MCR-18-1045","article-title":"Characterization of HCC mouse models: Towards an etiology-oriented subtyping approach","volume":"17","author":"Friemel","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119102_bib37","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ijc.32564","article-title":"Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification","volume":"146","author":"Hu","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2026.119102_bib38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119102_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:45:08Z","timestamp":1781880308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226001344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S0753332226001344"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119102","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti\u2013PD1 in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119102"}}